Compare UiPath Inc (PATH) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? UiPath Inc trades at $13.01 (market cap $6.91B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: UiPath Inc and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PATH | SYRE | |
|---|---|---|
Market Cap | $6.91B | $7.52B |
Volume | 26,239,123 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $19.29 | $108.92 |
52-Week Low | $9.38 | $22.18 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $5.70B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.06, down 1.95% on the day, with a bullish technical signal from moving averages but neutral oscillators. Revenue growth is robust, increasing from $1.3B in 2024 to $1.43B in 2025, with a projected net profit of $362M in 2026. Recent news highlights expanded AI partnerships and raised guidance, though the stock faces near-term volatility.
The outlook is cautiously optimistic, with a consensus price target of $15.13 offering potential upside. Key opportunities include strong enterprise demand and AI monetization, while risks involve competitive pressures and execution challenges in achieving profitability targets. Analyst sentiment is mixed, with a majority hold rating.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
